Today: 9 June 2026
Browse Category

NASDAQ:CYPH 12 November 2025 - 10 December 2025

Cypherpunk Technologies (CYPH) Stock: Zcash Treasury Pivot, Winklevoss Backing and 2026 Forecast Explained

Cypherpunk Technologies (CYPH) Stock: Zcash Treasury Pivot, Winklevoss Backing and 2026 Forecast Explained

Cypherpunk Technologies Inc. (NASDAQ: CYPH), formerly Leap Therapeutics, closed at $1.62 on December 9, 2025, up nearly 40% after pivoting from biotech to a Zcash-focused treasury strategy backed by Winklevoss Capital. The stock has seen trading halts, insider sales, and sharp volatility since the rebrand and $58.88 million private placement in October.
10 December 2025
·····
Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Aimei Health Technology shares surged 968% to $85.47 Tuesday after the SPAC extended its merger deadline to January 6, 2026, fueling speculation of a pending deal. The S&P 500 closed down 0.02%, while microcap stocks dominated gains, with Oriental Culture Holding up 321% and Netcapital up 122%. Trading in AFJK exceeded 6 million shares, far above its average.
9 December 2025
··········
Cypherpunk Technologies (CYPH) Soars Over 300% on Zcash Pivot – What’s Driving Today’s Volatile Rally? (17 November 2025)

Cypherpunk Technologies (CYPH) Soars Over 300% on Zcash Pivot – What’s Driving Today’s Volatile Rally? (17 November 2025)

Cypherpunk Technologies (NASDAQ: CYPH) shares jumped over 30% in U.S. pre-market trading Monday, reaching about $3.60 and a $155 million market cap. The move follows last week’s rebrand from Leap Therapeutics and a $50 million Zcash purchase backed by Winklevoss Capital. CYPH stock has surged more than 300% since its Nasdaq debut under the new ticker on November 13.
17 November 2025
··
Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

Cypherpunk Technologies (CYPH) Soars After Zcash Pivot: What Investors Need to Know on November 14, 2025

Cypherpunk Technologies (CYPH), formerly Leap Therapeutics, surged 70–90% intraday to over $3.00 on November 14, with trading volume topping 200 million shares. The company rebranded and spent $50 million to buy about 1.25% of Zcash’s supply after a private placement led by Winklevoss Capital. CYPH’s stock saw extreme volatility, swinging over 100 percentage points during the session.
14 November 2025
··
Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

CYPH Debuts: Cypherpunk Technologies (ex‑Leap Therapeutics) starts trading, files $200M ATM, posts Q3 results and details $50M Zcash treasury — 13 Nov 2025

Cypherpunk Technologies Inc., formerly Leap Therapeutics, began trading as CYPH on Nasdaq Thursday after shifting its focus from cancer drugs to a digital-asset treasury strategy centered on Zcash. Shares swung between $1.34 and $1.98 in volatile trading. The company disclosed a $50 million Zcash purchase and filed to sell up to $200 million in stock through Cantor Fitzgerald. Q3 net loss narrowed to $3.3 million.
13 November 2025
··
Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

Leap Therapeutics rebranded as Cypherpunk Technologies Inc. and changed its Nasdaq ticker from LPTX to CYPH on November 13, 2025. The company raised $58.88 million in a private placement led by Winklevoss Capital and spent $50 million buying 203,775 Zcash. Shares surged up to 440% after the announcement, with LPTX trading near $2.05 and ZEC at $502 early Thursday. Q3 results show a sharply reduced net loss as biotech spending falls.
13 November 2025
···
Leap Therapeutics (LPTX) Rebrands as “Cypherpunk,” Buys $50M in Zcash; Ticker to Change to CYPH on Nov. 13 — Q3 Results and New $200M ATM Filed (Nov. 12, 2025)

Leap Therapeutics (LPTX) Rebrands as “Cypherpunk,” Buys $50M in Zcash; Ticker to Change to CYPH on Nov. 13 — Q3 Results and New $200M ATM Filed (Nov. 12, 2025)

Leap Therapeutics will rebrand as Cypherpunk Technologies and begin trading under the ticker CYPH on Nov. 13. The company disclosed it purchased about $50 million in Zcash for its new digital-asset treasury. Q3 net loss narrowed to $3.3 million from $18.2 million a year ago. A $200 million at-the-market equity program was filed with Cantor Fitzgerald.
12 November 2025
··

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop